Session: SAT 532-553-Hyperandrogenic Disorders
Poster Board SAT-550
Design: Cross-sectional analysis of a longitudinal cohort study
Setting: General community setting
Participants: Participants were women randomly selected from the Medicare database. Mailed survey data were collected by the ALSWH at four time points. Data from respondents to survey 4 (2006), aged 28-33 (n=9145) were analysed.
Main outcome measures: Self-reported PCOS, body mass index (BMI), fertility concerns, use of fertility therapies including ovulation induction and in-vitro fertilization (IVF).
Results: Self-reported PCOS prevalence was 5.8% (95% CI: 5.3%-6.4%) in these women aged 28 to 33. Compared to women not reporting PCOS, women with PCOS had higher BMI (by 3.0 kg/m2), were less likely to be using contraception (45% vs. 25%, p<0.001) and were more likely to be trying to conceive (49% vs. 36%, p=0.02). In women who have tried for pregnancy 72% of women with PCOS reported fertility concerns compared to 16% of women without PCOS (OR 11.16 (95% CI 10.9-20.0, p<0.001). Of those reporting fertility concerns, use of fertility hormone treatment was higher (55% vs. 22%, p<0.001) and the use of IVF was higher (21% vs 16%, p<0.0001) in women with PCOS compared to women without PCOS. Overall, there was no significant difference in pregnancy outcomes and number of children between women with and without PCOS.
Longitudinal analysis of fertility concerns and fertility treatment in this cohort of women with PCOS is currently underway.
Conclusions: In this large community-based cohort, self-reported infertility and use of fertility treatment was significantly higher in women with PCOS, yet family size was similar. Considering the prevalence and health and economic burden of PCOS and of fertility therapies, strategies aimed at optimising fertility in PCOS including early family initiation, healthy lifestyle and weight management, as well as psychological support for women with PCOS and infertility are clinically important to improve health outcomes in PCOS.
Nothing to Disclose: AEJ, JB, SR, SZ, DL, HJT
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters